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We have had three discussions this afternoon
concerning amenorrhea. and most of these have dealt
with the diagnosis of causative conditions. I am going
to discuss the treatment of these women.
Whether or not the woman wishes to conceive in
the immediate future determines the plan of treat
ment in most cases. If conception is desired. I believe
it should not be immediately assumed that the
amenorrhea is the sole cause of the infertility. I would
check patency of fallopian tubes and adequacy of the
husband's sperm production before treating for con
ception. Regardless of the plans for pregnancy.
however. it should be determined whether the woman
is merely not ovulating with adequate endogenous
ovarian estrogen production or whether the ovula
tory failure is associated with lack of estrogen as well.
The former might occur if pituitary gonadotropins
were reduced and/or the preovulatory LH surge were
absent. The latter condition may be due to failure
of production of pituitary gonadotropins or to meno
pause with elevated levels of pituitary gonadotropins.
Several brief case reports of women with
amenorrhea will follow. In some of these. there will
be organic disease of the extragenital endocrine
glands such as the thyroid gland, or the adrenal
gland, or the pituitary gland. In others, there will be
no identifiable extragenital endocrine disease: then
the treatment would vary depending on whether or
not the woman wishes to become pregnant.
Case I. This patient was a 35-year-old gravida I.
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para I. aborta O who was seen after having amenor
rhea for six months. She had noticed tachycardia,
sweats. and weight loss. The radioactive iodine
uptake was 80% in 24 hours: this is much higher than
normal for this laboratory. A diagnosis of hyper
thyroidism was made. The patient was treated with
radioactive iodine and had resumption of regular
menses after the second course of treatment. She is
not presently trying to become pregnant.
In preparing for this talk. I was looking for in
stances of thyroid disease that caused amenorrhea,
and I couldn't find any where hypothyroidism was
the etiologic factor. I am as aware as you all are of the
thousands of women who have taken thyroid medica
tion as treatment for amenorrhea. but in the patients·
charts to which I had access. I could not find one
where this was the real etiologic factor. I did find
the following case of hyperthyroidism.
Case 2. This was a 30-year-old gravida 11, para I
who had had amenorrhea for two years after a spon
taneous abortion. She had moderate hirsutism. but
no other virilizing signs. An endometrial biopsy
showed "resting endometrium," that is. proliferative
glands without mitotic activity. Thyroid studies were
normal. and two urinary 17-ketosteroid deter
minations were moderately elevated: 16.1 and 18.1
mg/24 hours. It was decided that this was a case of
adrenal androgenic hyperfunction. The patient was
initially treated with dexamethasone 2 mg three
times a day for 2 days. followed by 0.75 mg/day
for maintenance. Ultimately. this was reduced to
0.5 mg/day. Under this treatment, the urinary 17ketosteroids fell to 2. 7 mg/24 hours. Ovulatory
cycles began and conception occurred.
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Case 3. This was a 26-year-old gravida 11. para 2
who was seen because or amenorrhea and galac
torrhea since her last delivery two years earlier. This
patient had been worked up about a year pre
viously elsewhere and had had normal skull x-rays.
normal visual fields. and normal EEG. The skull
x-rays were repeated: this time a destructive lesion
of the sella was seen. and the visual tields had a
bilateral defect. A transsphenoidal removal or pru
lactin-producing pituitary adenoma was done leaving
the remainder of the pituitary gland. Following this.
spontaneous menses have returned and they are
ovulatory. The visual fields have also returned tu
normal.
The first three cases dealt with patients who had
organic diseases of extragenital endocrine glands.
The remaining four cases have nu identiliable ex
lragenital endocrine disease.
Case 4. This was a 20-year-uld gravida O "hose
menses began at age 13 and had occurred every 35
days lasting 7 days until two years earlier when
amenorrhea had begun. coinciding with the lirst year
of college. She had a history or having received
thyroid medication in the past although she had
received none for the preceding year. The l"ree T, was
1.5 mg%. a normal value. and the maturation index
was 0/65/35. Oral medroxyprogesterone was admin
istered. and the patient had withdrawal bleeding
after this. An extensive investigation was not dune.
but the medroxyprogesterone medication was con
tinued for 3 months. After this. spontaneous
cycles returned.
Patients who have endogenous estrogen can
usually be treated with only a pure progestin given at
monthly intervals. It is unlikely that they have
anything seriously wrong with their hypothalamic
pituitary axis. When given an exogenous progestin at
monthly intervals (we usually give medroxyproges
terone for 5 days beginning al cycle day 22).
monthly bleeding episodes usually result. Some
women who do not want to menstruate 13 times
a year will be given the medication two 10 rour
limes a year. I do not think it is good for endu
metrium to be continuously stimulated by estrogen.
whether it is endogenous or exogenous. because ur
the possibility of endometrial hyperplasia. and I
think that even if the woman is not enthusiastic
about menstruating, she should be given this medi
cation at least several times a year.
Case 5. This was an 18-year-old gravida O who
had onset or menses at age 10 and who had had
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menses every 31 days lasting 5 days until she
entered college. Prior to this, she had experienced
amenorrhea in the summer when she had gone
away to camp. but the amenorrhea had ceased
when she returned home. She had very slight
hirsutism. and there was no withdrawal bleeding
after medroxyprogesterone. The serum FSH and LH
were normal. Tests of thyroid function. skull x-rays.
and urinary 17-ketosteroids were normal. The patient
was treated with cyclic estrogens and progestins
(conjugated estrogens 1.25 mg daily for 21 days
with medroxyprogesterone 10 mg daily added on
treatment days 17-21).
The failure of withdrawal bleeding after
medruxyprogesterone alone in a patient who does
have "·ithdrawal bleeding after estrogen-priming be
fore a prugestin is given indicates lack of endo
genous estrogen production. The group or patients
without endogenous estrogen includes cases where
the defect is ovarian (such as agenesis. castration.
or premature menopause) as well as cases or pitui
tary failure (such as that secondary to defective
releasing factors. ablation by surgery or radiation.
and diseases such as Sheehan·s syndrome). If this
syndrome appears at a time when it is appropriate
for a woman to stop menstruating. as would be the
case if she were in her mid-40's. I don't think the
condition necessarily needs to be treated. Certainly
when it occurs in an 18-year-old girl. as this did.
I believe that it is reasonable to treat with estro
gen plus a progestin. This will result in regular
episodes of withdrawal bleeding.
Case 6. This was a 27-year-old gravida I. para I
who had become pregnant the first time without
dilliculty. but who had had amenorrhea for six years.
She desired pregnancy. She weighed 208 pounds. had
mild facial hirsutism. and normal adnexa. Urinary
17-ketosteroids were 4.4 mg/24 hours. a normal
value. The maturation index was 0/86/14: a Rubin's
test had shown tubal patency. and a postcoital test
had shown abundant sperm. After medroxyproges
lerone-induced withdrawal bleeding. this patient
was given clomiphene 50 mg daily for 5 days. and
she promptly became pregnant in the first month
of treatment.
When clomiphene is used. the pregnancy rate
will he around 30%. The incidence or ovulation is
much greater than 30%. but every patient who shows
evidence or ovulation does nut always become preg
nant. This may be due to the fact that we think the
p..:rsun is ovulating when she really is nut. All of our
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indices for detection of ovulation are based on the
effects of progesterone, because we know that in nor
mal women progesterone is present and exerts its
effect primarily after ovulation, and we assume that
this also happens in abnormal states. I am not ab
solutely sure that this is so, but I have no valid proof
that it is not. Ovulation apparently is induced. or at
least progesterone is produced, in about 70% of the
women receiving clomiphene, but pregnancy occurs
only in about 30%.
Sometimes couples will want to know when is
the best time for exposure after clomiphene to
achieve a pregnancy. It is my practice to tell the
patients to begin having regular intercourse about
four days after the last tablet and to continue this un
til the basal temperature has been up for three days.
Clomiphene is not without side effects. Ovarian
enlargement may occur in about 14% of patients. and
sometimes the ovaries become quite large. but the
problem is much less than with the agent that will be
dis�ssed shortly. Hot flashes are the common com
plaint that patients report. If patients are reassured
about this and told that they are not menopausal. it
does not seem to be a troublesome effect. The in
stance of multiple pregnancy is increased tenfold.
Under normal circumstances. the incidence of multi
ple pregnancy is around I in 80: with clomiphene it
will rise to around I in IO or I in 12. Blurring of vi
sion may occur in around I% of patients. and when
this occurs. it is an indication to discontinue the
medication. Spontaneous abortion occurs at a higher
rate than would be expected.
Case 7. This was a 29-year-old gravida I. para I.
aborta O who desired pregnancy and who had had
amenorrhea for nine months when she was first seen.
She had been on oral contraceptive medication prior
to her first pregnancy: this had been discontinued.
and she had conceived promptly without difficulty.
After that pregnancy, she took combination oral con
traceptive tablets for several years. Her other work
up had indicated that her thyroid function was nor
mal, that the blood FSH and LH were normal. and
that 17-ketosteroids were also normal. Tubal patency
and sperm production were adequate. Attempts to in
duce ovulation with clomiphene began with a low
dose of 50 mg daily for 5 days. This was raised
gradually to 200 mg/day for 5 days, with chorionic
gonadotropin added after this. This was not
successful; then treatment with menopausal-chori
onic gonadotropin was given according to the
outline in Table I.
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TABLE I
Outline of Gonadotropin Rx
lb Day
I
.1
4

8

9
10
II
12
13

Cervical
Mucus

0
0
0
I+
I+
2+
2+

3+

H
4+

Plasma

Estradiol

Rx

1.14 pg/ml
179 pg/ml
2.17 pg/ml
332 pg/1111
478 pg/ml
938 pg/ml

HMG 75-75 u.
HMG 150-150u.
HMG 150-150u.
HMG 150-150u.
HMG 150-150u.
HMG 225-225u.
HMG 300-300u.
HMG 300-300u.
HMG 300-300u.
HMG 10.000u.

BBT down
Sustained rise in BBT began. followed by menses.

1n such cases. one may get response to
menopausal plus chorionic gonadotropin. The in
stance of pregnancy with this treatment is around
25%. This treatment is also associated with side
effects. One has to be very careful in giving it.
Ovarian enlargement may occur in up to 20% of the
cases. and in extreme instances may be associated
with acites and even plural effusions. The cysts
may rupture. and there may be hemoperitoneum.
The severe hyperstimulation syndrome is found to
be associated with abdominal distention and
hemoconcentration (because so much of the body's
total fluid volume has gone into the abdominal
cavity). The treatment is bedrest. intravenous fluids
with close monitoring of electrolytes. and avoid
ance of pelvic examinations. This can become
serious. can lead to thrombosis. and there have been
several deaths. The instance of multiple pregnancy
with menopausal-chorionic gonadotropin treatment
is 20-37%. and the instance of abortion is around
28%: an incidence greater than would be expected
with normal spontaneous ovulation. In one series, it
was found that three-fourths of the multiple pregnan
cies were twins. and one-fourth of the multiple preg
nancies were three or more.
There are several problems in treating women
with gonadotropins. One wants to give enough
medication to induce ovulation, but not so much that
the hyperstimulation syndrome is produced. In
this particular patient, the menopausal gonadotropin
dosage was gradually increased until day IO when
good cervical mucus was seen, indicating that,
more than likely, enough medication had been.
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given. Laboratory tests of estrogen production
were done to determine that too much had not
been given. In many institutions. the determination is
of urinary estrogen. but at the Medical College or
Virginia there is a technique whereby plasma es
tradiol can be measured in about six hours. The
patients have blood drawn in the morning and return
at 4:00 p.m .. at which time the laboratory data is
available. The aim is to reach a level or between 500
and IOOO pg/ml of estradiol. If the level stays un
der IOOO pg/1111. the incidence of hyperstirnulation
syndrome is much less than if the level is higher.
If this patient had been given another day or treat
ment. a situation might have been created where
hyperstimulation would have occurred. The patient
did not become pregnant. although evidence for
ovulation was obtained from basal temperature
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charts. I want to emphasize this because I think this is
a way a physician can get in trouble. One can decide
when he has given enough estrogen by the effect on
cervical mucus. but one cannot tell when he has given
too much. If estradio I levels are too high, one would
not give chorionic gonadotropin, stop the treatment,
and try again in a month or so, giving less medi
cation. I think to avoid serious complications in
treating a nonlethal condition. there has to be some
way of assessing the estrogen production from the
stimulated ovaries.
I have tried to illustrate the treatment for
amenorrhea of different causes and to emphasize the
fact that the treatment is different when the woman
wishes or does not wish to become pregnant. I have
also pointed out some of the hazards of the various
methods of treatment of this condition.

